Antipsychotic treatment of psychosis associated with multiple sclerosis

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 28, Issue 4, 2004, Pages 743-744

  Davids, Eugen ^a   Hartwig, Ulrike ^a   Gastpar, Markus ^a  

^a UNIVERSITY OF DUISBURG ESSEN   (Germany)

Author keywords

Antipsychotic drugs; EPS; extrapyramidal side effects; magnetic resonance imaging; MRI; MS; Multiple sclerosis; multiple sclerosis; Psychosis; Ziprasidone

Indexed keywords

BENZODIAZEPINE; CORTICOSTEROID; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; TRIMIPRAMINE; ZIPRASIDONE;

ADULT; AGITATION; ANAMNESIS; ARTICLE; CASE REPORT; CLINICAL FEATURE; DIZZINESS; DRUG TOLERABILITY; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HUMAN; LABORATORY TEST; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PSYCHOSIS; QT PROLONGATION;

ANTIPSYCHOTIC AGENTS; FEMALE; HUMANS; MIDDLE AGED; MULTIPLE SCLEROSIS; PIPERAZINES; PSYCHOTIC DISORDERS; SCHIZOPHRENIC PSYCHOLOGY; THIAZOLES;

EID: 3342958247     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2004.05.010     Document Type: Article

References (12)

1. Caley C.F., Cooper C.K. Ziprasidone: the fifth atypical antipsychotic. Ann. Pharmacother. 36:2002;839-851
2. Chong S.A., Ko S.M. Clozapine treatment of psychosis associated with multiple sclerosis. Can. J. Psychiatry. 42:1997;90-91
3. Citrome L., Volavka J. Optimal dosing of atypical antipsychotics in adults: a review of the current evidence. Harv. Rev. Psychiatr. 10:2002;280-291
4. Heckers S., Anick D., Boverman J.F., Stern T.A. Priapism following olanzapine administration in a patient with multiple sclerosis. Psychosomatics. 39:1998;288-290
5. Offenbacher H., Fazekas F., Schmidt R., Freidl W., Flooh E., Payer F., Lechner H. Assessment of MRI criteria for a diagnosis of MS. Neurology. 43:1993;905-909
6. Pine D.S., Douglas C.J., Charles E., Davies M., Kahn D. Patients with multiple sclerosis presenting to psychiatric hospitals. J. Clin. Psychiatry. 56:1995;297-306
7. Poser C.M., Paty D.W., Scheinberg L., McDonald W.I., Davis F.A., Ebers G.C., Johnson K.P., Sibley W.A., Silberberg D.H., Tourtellotte W.W. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann. Neurol. 13:1983;227-231
8. Safferman A.Z., Kane J.M., Aronowitz J.S., Gordon M.F., Pollack S., Lieberman J.A. The use of clozapine in neurologic disorders. J. Clin. Psychiatry. 55(9 Suppl.):1994;98S-101S
9. Schifferdecker M., Krahl A., Krekel N.O. Psychosen bei multipler Sklerose-eine Neubewertung. Fortschr. Neurol. Psychiatr. 63:1995;310-319
10. Stevens J.R. Schizophrenia and multiple sclerosis. Schizophr. Bull. 14:1998;231-241
11. Stimmel G.L., Gutierrez M.A., Lee V. Ziprasidone: an atypical antipsychotic drug for the treatment of schizophrenia. Clin. Ther. 24:2002;21-37
12. Zipoli V., Portaccio E., Siracusa G., Pracucci G., Sorbi S., Amato M.P. Interobserver agreement on Poser's and the new McDonald's diagnostic criteria for multiple sclerosis. Mult. Scler. 9:2003;481-485